SPTLC1

Across TCGA pan-cancer cohorts, SPTLC1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SPTLC1 data layer compared with 20 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SPTLC1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SPTLC1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, COAD, and LUAD are the cancer types where SPTLC1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	III,IV	0.818	0.488	.010	18	view →
COAD	DFS	Median	IV	0.565	1.000	.028	6	view →
LUAD	DFS	Tertile	II,III,IV	0.262	0.811	.014	5	view →
PDAC	DFS	Median	All	0.264	0.442	.023	2	view →
CCRCC	OS	Tertile	All	0.642	1.000	.030	2	view →
LSCC	DFS	Quartile	II,III,IV	0.870	0.544	.033	1	view →
GBM	OS	Median	All	0.539	0.285	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SPTLC1–HNSC (DFS)

Open the HNSC breakdown →